Croda celebrates EXCiPACT Certification across all leading excipient sites

Status marks the company as the first multi-site excipient supplier to achieve global EXCiPACT accreditation across its production facilities.

This achievement reflects 10 years’ worth of efforts by Croda’s Head of Global Quality Assurance, Dr Iain Moore, and the site teams. Iain has been heavily involved in shaping EXCiPACT and has been singled out by IPEC as a "leading light" in driving the accreditation forward. Back in 2014, Croda’s Rawcliffe Bridge site became one of the first few sites awarded the prestigious EXCiPACT Certificate. Since then, six other Croda manufacturing sites have been certified, accounting for over 90% of Croda’s excipient production.

Manufacturing processes, quality systems, quality management and the storage and distribution of pharmaceutical excipients have been inspected throughout the audits. The global certifications assure optimal product quality and security within the supply chain in order to guarantee product safety for our customers and ultimately, patients.

Dave Cherry, Managing Director of Croda’s Health Care business said: "This achievement brings significant value to both Croda and our customers, reducing the audit burden on both sides whilst maintaining confidence in Croda's compliance to the demanding standards of the Pharmaceutical industry. The certificate assures our customers that Croda manufactures and distributes pharmaceutical excipients to EXCiPACT good manufacturing (GMP) standards. It is a measure of excellence in quality and an assurance for our customers that they are always in receipt of material of the highest standards."